Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
AXAxsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM)

NASDAQ Global Market · Currency in USD
$145.04 ▼ -11.03 (-7.07%)
At close: Oct 23, 4:00 PM ET. Market closed.
$146.92 ▲ +1.88 (+1.30%)
After hours: Oct 23, 7:45 PM ET

Summary

Previous Close
$156.07
Open
$154.30
Day's Range
$143.90 – $154.74
52 Week Range
$123.50 – $260.19
Volume
1,593,180
Avg. Volume
848,729
Market Cap
$7.60B
Beta (5Y Monthly)
0.60
PE Ratio (TTM)
--
EPS (TTM)
-$3.72
Earnings Date
Nov 2, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$283.00

Profile: Axsome Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
1,346
CEO
Herriot Tabuteau
Website
axsome.com

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation.

Earnings

Next report: Mon, Nov 2, 2026
EPS estimate -$0.62 · Revenue est. $250.22M
DateEst.Actual
Aug 10, 2026-$0.89-$0.99Miss
May 4, 2026-$0.85-$1.26Miss
Feb 23, 2026-$0.70-$0.71Miss
Nov 3, 2025-$0.82-$0.94Miss
Aug 4, 2025-$1.00-$0.92Beat
May 5, 2025-$1.26-$1.22Beat

Analyst view

Consensus price target
$283.00 ▲ +95.1%
Range $246.00 – $380.00
Rating: Buy
Buy 96% · Hold 4% · Sell 0%

Get free alerts on AXSM and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.